Related Experiment Video
Updated: Jun 29, 2026
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Increased expressions of cannabinoid receptor-1 and transient receptor potential vanilloid-1 in human prostate
Gabriella Czifra1, Attila Varga, Katalin Nyeste
1Department of Physiology, Medical and Health Science Center, Research Center for Molecular Medicine, University of Debrecen, Debrecen, Hungary.
Purpose:
Recently, functional cannabinoid receptor-1 (CB1) and vanilloid receptor-1 (TRPV1) have been described in human prostate and prostate cancer-derived cell lines where the activation of the receptors resulted in inhibition of cellular growth. We, however, lack the description of the expression of these molecules in human prostate cancer (PCC) and in benign prostate hyperplasia (BPH).
Methods:
Therefore, immunohistochemistry, Western blotting, and quantitative "real-time Q-PCR were performed to define the expressions of CB1 and TRPV1 in healthy and diseased prostate tissues.
Results:
CB1 was identified in epithelial and smooth muscle cells types of the human prostate, whereas TRPV1 was exclusively localized to the mucosal cells. We also found that the expression of CB1 and TRPV1 (both at the protein and mRNA levels) were significantly up-regulated in PCC. However, while the increased expression of TRPV1 showed a proper correlation with increasing PCC tumor grades, such phenomenon was not observed with CB1. In addition, we also measured markedly elevated CB1 levels in BPH tissues whilst the expression of TRPV1 was not altered when compared to healthy control prostate.
Conclusions:
Our findings strongly argue for that (1) the CB1 and TRPV1 molecules as well as their ligands may indeed possess a promising future role in the treatment of PCC; (2) TRPV1 may also serve as a prognostic factor in PCC; and (3) CB1 may act as a potential target molecule in the therapeutic management of BPH.
Insights
Cannabinoid receptor-1 (CB1) and TRPV1 are upregulated in prostate cancer (PCC). TRPV1 correlates with tumor grade, while CB1 is elevated in benign prostatic hyperplasia (BPH), suggesting therapeutic potential for both conditions.
Area of Science:
- Urology
- Oncology
- Molecular Biology
Background:
- Cannabinoid receptor-1 (CB1) and vanilloid receptor-1 (TRPV1) are present in prostate cells.
- Activation of CB1 and TRPV1 has shown potential to inhibit cellular growth in prostate cancer cell lines.
Purpose of the Study:
- To investigate the expression of CB1 and TRPV1 in human prostate cancer (PCC) and benign prostatic hyperplasia (BPH).
- To determine the correlation of CB1 and TRPV1 expression with PCC tumor grade and BPH.
Main Methods:
- Immunohistochemistry, Western blotting, and quantitative real-time PCR were employed.
- Analysis was performed on healthy prostate tissue, PCC, and BPH samples.
Main Results:
- CB1 was found in epithelial and smooth muscle cells; TRPV1 was localized to mucosal cells.
- Both CB1 and TRPV1 mRNA and protein levels were significantly upregulated in PCC.
- TRPV1 expression correlated with PCC tumor grade, while CB1 was elevated in BPH but not in PCC tumor grade.
Conclusions:
- CB1 and TRPV1 show promise as therapeutic targets for prostate cancer treatment.
- TRPV1 may serve as a prognostic biomarker for prostate cancer.
- CB1 represents a potential therapeutic target for managing benign prostatic hyperplasia.
Related Concept Videos
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
02:23Abnormal Proliferation